TY - JOUR
T1 - NCCN guidelines® Insights
T2 - Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines
AU - Ettinger, David S.
AU - Wood, Douglas E.
AU - Akerley, Wallace
AU - Bazhenova, Lyudmila A.
AU - Borghaei, Hossein
AU - Camidge, David Ross
AU - Cheney, Richard T.
AU - Chirieac, Lucian R.
AU - D'Amico, Thomas A.
AU - Dilling, Thomas J.
AU - Chris Dobelbower, M.
AU - Govindan, Ramaswamy
AU - Hennon, Mark
AU - Horn, Leora
AU - Jahan, Thierry M.
AU - Komaki, Ritsuko
AU - Lackner, Rudy P.
AU - Lanuti, Michael
AU - Lilenbaum, Rogerio
AU - Lin, Jules
AU - Loo, Billy W.
AU - Martins, Renato
AU - Otterson, Gregory A.
AU - Patel, Jyoti D.
AU - Pisters, Katherine M.
AU - Reckamp, Karen
AU - Riely, Gregory J.
AU - Schild, Steven E.
AU - Shapiro, Theresa A.
AU - Sharma, Neelesh
AU - Stevenson, James
AU - Swanson, Scott J.
AU - Tauer, Kurt
AU - Yang, Stephen C.
AU - Gregory, Kristina
AU - Hughes, Miranda
N1 - Copyright © 2016 by the National Comprehensive Cancer Network.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
AB - These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
KW - Antibodies, Monoclonal, Humanized/adverse effects
KW - Antibodies, Monoclonal/adverse effects
KW - Antineoplastic Agents/adverse effects
KW - Carcinoma, Non-Small-Cell Lung/drug therapy
KW - Carcinoma, Squamous Cell/drug therapy
KW - Docetaxel
KW - Humans
KW - Immunosuppressive Agents/adverse effects
KW - Immunotherapy/methods
KW - Lung Neoplasms/drug therapy
KW - Nivolumab
KW - Practice Guidelines as Topic
KW - Survival Rate
KW - Taxoids/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=84961575658&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000371997900006&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2016.0031
DO - 10.6004/jnccn.2016.0031
M3 - Review article
C2 - 26957612
SN - 1540-1405
VL - 14
SP - 255
EP - 264
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 3
ER -
